Notably, increased numbers of samples from patients with large-cell neuroendocrine carcinomas (LCNEC) and patients with stage T2 (six out of eight and 25 out of 45, respectively) were MYC positive (copy number ≥ 2.19), but differences were statistically not significant. Here, MYC is linked to large cell neuroendocrine carcinoma.